SCHEMBL3006480

SCHEMBL3006480

CCOc1ccc(Cc2csc(N3CCC(S(=O)(=O)c4cccc(Cl)c4)CC3)n2)cc1

nearest known ligand 0.41

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
LMNA P02545 3/20 0.41
MAPT P10636 5/20 0.39
TP53 P04637 3/20 0.38
SMN1; SMN2 Q16637 3/20 0.38
ALOX15 P16050 1/20 0.37
RAB9A P51151 2/20 0.37
CNR2 P34972 1/20 0.36
THRB P10828 1/20 0.36
TDP1 Q9NUW8 1/20 0.36
PTGDR2 Q9Y5Y4 1/20 0.35
MEN1 O00255 1/20 0.35
KMT2A Q03164 1/20 0.35
F2 P00734 1/20 0.35
F2RL3 Q96RI0 1/20 0.35
MAPK14 Q16539 1/20 0.35
KDM4E B2RXH2 1/20 0.35
NPC1 O15118 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3011307 0.93 MAPT (0.41) LMNAMAPTTP53SMN1; SMN2RAB9A
SCHEMBL3010954 0.91 KCNQ1 (0.42) LMNAMAPTTP53SMN1; SMN2RAB9A
SCHEMBL3264261 0.90 RAB9A (0.39) LMNAMAPTSMN1; SMN2RAB9AMEN1
SCHEMBL3014963 0.90 GPR6 (0.40) LMNAMAPTTP53SMN1; SMN2KDM4E
SCHEMBL3017067 0.90 RORC (0.37) LMNAMAPTTP53SMN1; SMN2RAB9A
SCHEMBL3019320 0.90 MAPT (0.47) LMNAMAPTTP53SMN1; SMN2RAB9A
SCHEMBL3003047 0.89 RAB9A (0.41) MAPTSMN1; SMN2RAB9AMEN1KMT2A
SCHEMBL3011356 0.89 MAPT (0.39) LMNAMAPTTP53SMN1; SMN2RAB9A
SCHEMBL3016036 0.89 RAB9A (0.38) MAPTSMN1; SMN2RAB9ANPC1
SCHEMBL3013025 0.89 SMN1; SMN2 (0.39) LMNAMAPTTP53SMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8722681-B2 N-sulfonyl thiazolylpiperazine derivatives and related N-sulfonyl heterocyclic derivatives for the treatment of neuro degenerative diseases NV REMYND (BE) 2014-05-13 US disclosed
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES NV REMYND (BE) 2010-08-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100197703-A1 N-SULFONYL THIAZOLYLPIPERAZINE DERIVATIVES AND RELATED N-SULFONYL HETEROCYCLIC DERIVATIVES FOR THE TREATMENT OF NEURO DEGENERATIVE DISEASES SMN1; SMN2, HTT, SNCA LMNA 80/4885MAPT 18/4885TP53 2880/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.